Author:
Oosthuyse Bert,Moons Lieve,Storkebaum Erik,Beck Heike,Nuyens Dieter,Brusselmans Koen,Dorpe Jo Van,Hellings Peter,Gorselink Marchel,Heymans Stéphane,Theilmeier Gregor,Dewerchin Mieke,Laudenbach Vincent,Vermylen Patrick,Raat Harold,Acker Till,Vleminckx Vicky,Bosch Ludo Van Den,Cashman Neil,Fujisawa Hajime,Drost Maarten R.,Sciot Raf,Bruyninckx Frans,Hicklin Daniel J,Ince Can,Gressens Pierre,Lupu Florea,Plate Karl H.,Robberecht Wim,Herbert Jean-Marc,Collen Désiré,Carmeliet Peter
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nature Med. 6, 389–395 (2000).
2. Ferrara, N. & Alitalo, K. Clinical applications of angiogenic growth factors and their inhibitors. Nature Med. 5, 1359–1364 (1999).
3. Miao, H.Q. et al. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J. Cell. Biol. 146, 233–242 (1999).
4. Soker, S., Takashima, S., Miao, H.Q., Neufeld, G. & Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform- specific receptor for vascular endothelial growth factor. Cell 92, 735–745 (1998).
5. van Bruggen, N. et al. Vegf antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J. Clin. Invest. 104, 1613–1620 (1999).